Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 90 of the 92 references it cites were found in a registry or an index.

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

Open access

Abstract

Non-alcoholic fatty liver disease ranges from steatosis to non-alcoholic steatohepatitis (NASH), potentially progressing to cirrhosis and hepatocellular carcinoma (HCC). Here, we show that platelet number, platelet activation and platelet aggregation are increased in NASH but not in steatosis or insulin resistance. Antiplatelet therapy (APT; aspirin/clopidogrel, ticagrelor) but not nonsteroidal anti-inflammatory drug (NSAID) treatment with sulindac prevented NASH and subsequent HCC development. Intravital microscopy showed that liver colonization by platelets depended primarily on Kupffer cells at early and late stages of NASH, involving hyaluronan-CD44 binding. APT reduced intrahepatic platelet accumulation and the frequency of platelet-immune cell interaction, thereby limiting hepatic immune cell trafficking. Consequently, intrahepatic cytokine and chemokine release, macrovesicular steatosis and liver damage were attenuated. Platelet cargo, platelet adhesion and platelet activation but not platelet aggregation were identified as pivotal for NASH and subsequent hepatocarcinogenesis. In particular, platelet-derived GPIbα proved critical for development of NASH and subsequent HCC, independent of its reported cognate ligands vWF, P-selectin or Mac-1, offering a potential target against NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0379-5

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 92 references

Research works printed but not linked: 1

  1. European Commission. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Med Etika Bioet. 9, 12–19 (2002).

Cited by

See all 399

Metadata

Authors
Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., Ali, A., Wolf, M. J., Drescher, H., Healy, M. E., Dauch, D., Kroy, D., Krenkel, O., Kohlhepp, M., Engleitner, T., Olkus, A., Sijmonsma, T., Volz, J., Deppermann, C., Stegner, D., Helbling, P., Nombela-Arrieta, C., Rafiei, A., Hinterleitner, M., Rall, M., Baku, F., Borst, O., Wilson, C. L., Leslie, J., O’Connor, T., Weston, C. J., Chauhan, A., Adams, D. H., Sheriff, L., Teijeiro, A., Prinz, M., Bogeska, R., Anstee, N., Bongers, M. N., Notohamiprodjo, M., Geisler, T., Withers, D. J., Ware, J., Mann, D. A., Augustin, H. G., Vegiopoulos, A., Milsom, M. D., Rose, A. J., Lalor, P. F., Llovet, J. M., Pinyol, R., Tacke, F., Rad, R., Matter, M., Djouder, N., Kubes, P., Knolle, P. A., Unger, K., Zender, L., Nieswandt, B., Gawaz, M., Weber, A., & Heikenwalder, M.
Affiliations
  • University of Zurich (CH)
  • German Cancer Research Center (DE)
  • University of Calgary (CA)
  • University of Tübingen (DE)
  • Universitätsklinikum Aachen (DE)
  • Universitätsklinikum Tübingen (DE)
  • University of Würzburg (DE)
  • Newcastle University (GB)
  • Helmholtz Munich (DE)
  • National Institute for Health and Care Research (GB)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • University of Birmingham (GB)
  • Spanish National Cancer Research Centre (ES)
  • University of Freiburg (DE)
  • MRC London Institute of Medical Sciences (GB)
  • University of Arkansas for Medical Sciences (US)
  • Monash University (AU)
  • Institució Catalana de Recerca i Estudis Avançats (ES)
  • Hospital Clínic de Barcelona (ES)
  • University Hospital of Basel (CH)
  • Technical University of Munich (DE)
Corresponding author
Weber, Achim
Venue
Nature Medicine
Published
2019-04
Volume
25
Issue
4
Pages
641-655
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2934212324
Cited by
398
References
92
Citations by year
2026: 48 · 2025: 51 · 2024: 55 · 2023: 57 · 2022: 73 · 2021: 55 · 2020: 41 · 2019: 17
FWCI
35.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Wellcome Trust (098565/Z/12/Z)
  • Cancer Research UK (26813, 23390)
  • National Institute for Health and Care Research (NF-SI-0512-10080, NF-SI-0616-10012)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (182764, 320030)
  • Medical Research Council (MR/M009157/1, MR/K001949/1, MC_PC_14123)
  • National Cancer Institute (P30CA196521)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
nonalcoholic steatohepatitis, hepatocellular carcinoma, platelet activation, platelet aggregation, antiplatelet therapy, Kupffer cells, macrovesicular steatosis, hepatocarcinogenesis, platelet adhesion, non-alcoholic fatty liver disease
MeSH terms
Animals, Blood Platelets, Body Weight, Cytoplasmic Granules, Endothelium, Humans, Hyaluronic Acid, Kupffer Cells, Liver, Liver Neoplasms, Mice, Transgenic, Platelet Aggregation, Platelet Aggregation Inhibitors, Platelet Count, Cytokines, Hyaluronan Receptors, Platelet Glycoprotein GPIb-IX Complex, Hepatocytes, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. https://app.cochat.ai/papers/10.1038/s41591-019-0379-5
The paper
Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., Ali, A., Wolf, M. J., Drescher, H., Healy, M. E., Dauch, D., Kroy, D., Krenkel, O., Kohlhepp, M., Engleitner, T., . . . Heikenwalder, M. (2019). Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nature Medicine. https://doi.org/10.1038/s41591-019-0379-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.